

Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults

© Nurdan Şentürk Durmuş¹, © Sibel Akın¹, © Tuba Soysal¹, © Gözde Ertürk Zararsız², © Zeynep Türe³

¹Erciyes University Faculty of Medicine, Department of Internal Medicine, Clinic of Geriatrics, Kayseri, Turkey

²Erciyes University Faculty of Medicine, Department of Biostatistics, Kayseri, Turkey

³Erciyes University Faculty of Medicine, Department of Clinical Microbiology and Infectious Diseases, Kayseri, Turkey

Abstract

Objective: This study aims to determine the relationship between polypharmacy and Coronavirus disease 19 (COVID-19) (+) related mortality.

Materials and Methods: All older adults >60 years old who had positive COVID-19 PCR tests were included in the study, designed retrospectively. Polypharmacy was defined as drug use of five or more.

Results: One hundred and ten people of > 60 years old were included in the study. Fifty-nine (53.6%) of the participants were male and the mean age was 70.5 + 8.81. The prevalence of polypharmacy in patients diagnosed with COVID-19 infection was 31.8% (n=35). Eighty-two (78.8%) of participants had pneumonia. Mortality occurred in 24 (21.8%) of the participants. There was no relationship between polypharmacy and mortality (p=0.241). In multivariate analysis, older age was associated with mortality (Odds ratio: 6.82 95% CI 2.46-18.91, p <0.001).

Conclusion: The prevalence of polypharmacy in individuals diagnosed with COVID-19 infection was like the literature. The most significant factors in death in people with COVID-19 infection were older age. There was no relationship between polypharmacy and mortality.

Keywords: Older age, COVID, polypharmacy, mortality, coronavirus

Introduction

The pandemic of Coronavirus disease 19 (COVID-19), which started in China in December 2019, caused the death of 1.311.942 people, infecting about 54 million people worldwide by 15 November 2020 [1]. COVID-19 infection can be asymptomatic-mild upper respiratory tract infection or it can present with pneumonia and, acute respiratory distress syndrome [2-5]. In many studies on COVID-19, older age and comorbidity has been associated with poor outcomes [2, 3, 5-7]. Results are worse in older adult individuals who need mechanical ventilation [3].

In Turkey, the first case was reported on 11 March 2020 - the first death was seen on 17 March 2020 [8]. By 10 February 2021, total cases and deaths had reached 2.548.195 and 26.998 cases in Turkey, respectively [8].

With aging, the number of diseases increases; therefore, the number of drugs used by people increases [9]. Polypharmacy

is an acute geriatric syndrome [10]. Polypharmacy incidence has been reported from 30% to 60 % in older adults [10-12]. The reason for such a difference in polypharmacy incidence is that there is no universal definition of polypharmacy [10]. Some define it as drug use other than indication [12], while others define it with more drug use than a certain number of drugs [10, 13]. Polypharmacy has been associated with many clinical conditions such as falls, mortality, adverse drug events, impaired cognition, and frailty [10, 11, 14]. Until now, many factors related to mortality have been revealed in patients with a diagnosis of COVID-19, but there are a limited number of studies evaluating them in terms of geriatric syndromes [3, 6, 15]. In the studies performed, mortality with frailty was evaluated, and unlike expectedly, no relation with mortality in frail patients was shown [6, 15]. There are few studies of the relationship between polypharmacy and COVID-19 related mortality, and their results are conflicting [3, 6].

Address for Correspondence: Sibel Akın, Erciyes University Faculty of Medicine, Department of Internal Medicine, Clinic of Geriatrics, Kayseri, Turkey

Phone: +90 352 207 66 66 (21916) **E-mail:** sibelyanmaz@gmail.com **ORCID:** orcid.org/0000-0002-6139-7254

Received: 08.01.2021 **Accepted:** 03.03.2021

Cite this article as: Şentürk Durmuş N, Akın S, Soysal T, Ertürk Zararsız G, Türe Z. Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults.

This study aimed to clarify the relationship between COVID-19 and polypharmacy because the research results published so far are contradictory. This study aims to determine the prevalence of polypharmacy in patients diagnosed with COVID-19 (+), to investigate whether the presence of polypharmacy in patients with COVID-19 (+) has an impact on mortality, and to identify other causes of mortality in people diagnosed with COVID-19 (+).

Materials and Methods

All older adults >60 years old who had a positive COVID-19 PCR test at Erciyes University Medical School Hospital were included in the study. Erciyes University Medical School Hospital was the reference hospital for the pandemic. This research had been designed retrospectively. For the retrospective design, we did not evaluate the comprehensive geriatric assessment and frailty status of patients.

The files of the participants included in the study were scanned retrospectively. Their sociodemographic characteristics (age, gender), comorbidities (e.g., chronic obstructive pulmonary disease [COPD], cancer, hypertension [HT], coronary artery disease [CAD], chronic kidney disease [CKD], and/or diabetes mellitus [DM]), the number of drugs, the types of drugs, the presence of pneumonia, the history of admission on intensive care unit (ICU), the history of mechanical ventilation and the presence of mortality were recorded.

COVID-19 was detected by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay of samples collected by using nasopharyngeal swabs. Computed tomography (CT) was performed on all patients without contraindications (claustrophobia, etc.), who resulted in COVID-19 PCR positive. A specialist radiologist evaluated CT. Patients with infiltration on CT were considered to have COVID-19 pneumonia.

In this study, five or more drug use was defined as polypharmacy [10]. When the patients admitted to the hospital, those who used five or more medications regularly for the last year were accepted as "polypharmacy". The drugs were recorded through the patients' reports during hospitalization and controlled from the medulla system (in Turkey). The drugs used by the patients were categorized as antihypertensive, antiaggregant, anticoagulant, antidepressant, antidiabetic (AD) drugs, inhaler drugs, antilipidemic drugs, immunosuppressant drugs, and proton pump inhibitors.

This research was approved by the Erciyes University Ethics Committee. Consent was obtained from the participants or their relatives.

Statistics

Histogram, q-q plots are examined, and the Shapiro-Wilk's test was applied to assess the data normality. Levene test was used to

test variance homogeneity. To compare the differences between groups, the Pearson chi-square test or Fisher's exact test were applied for categorical variables to compare the differences between groups. Mann-Whitney U tests were applied for continuous variables. Binary logistic regression analysis models were built to investigate the effect of variables in estimating mortality in geriatric patients. Crude, age, and gender-adjusted, and multiple models were fitted separately. Significant variables at $p < 0.25$ were included in numerous models, and backward elimination was performed to identify independent risk factors. Wald statistic was used as a model selection criterion. Hosmer Lemeshow tests were used for the goodness of fit test. Odds ratios were calculated with 95% confidence intervals. All analyses were performed using TURCOsa (Turcosa Analytics Ltd. Co., www.turcosa.com.tr) statistical software. p values less than 5% were considered as statistically significant.

Results

One hundred ten people of > 60 years old were included in this research. Fifty-nine (53.6%) of the participants were male and the mean age was 70.5 (64.0-78.2, standard deviation 8.81). Ninety-five (86.4%) of the participants had comorbidities. The most common comorbidity was HT with 61.8% ($n=68$) patients, the second was DM with 28.2% ($n=31$) patients. Polypharmacy was recorded in 31.8% ($n=35$). The most widely used drugs were diuretics (hydroxychlorothiazide, spironolactone) ($n=41$, 37.3%), beta-blockers ($n=34$, 30.9%), acetyl-salicylic acid (ASA) ($n=32$, 29.1%), angiotensin receptor blockers (ARB) ($n=31$, 28.2%), calcium channel blockers ($n=26$, 23.6%), angiotensin-converting enzyme inhibitors (ACE-I) ($n=24$, 21.8%) and metformin ($n=21$, 19.1%). While a total of 78.8% ($n=82$) had COVID-19 pneumonia. Ten (9.1%) of 110 participants had a history of admission in ICU, and five (4.5%) had mechanical ventilation. Mortality occurred in 21.8% ($n=24$) of the participants. Table 1 shows the demographic and clinical characteristics of the participants according to mortality. The participants who had mortality were older (69 vs. 79.5, $p < 0.001$). Moreover, the mortality rate was higher in hospitalized individuals (69.8% vs. 100%, $p = 0.002$). Table 2 shows the relationship between drug groups and mortality. There was no relationship between any drug group and mortality. Thirteen (22.0%) of the patients with mortality were male and 21.6% ($n=11$) were female ($p = 0.570$). Twelve (13.8%) of those with mortality were between the ages of 60-79 and 52.2% ($n=12$) were over 80 years old ($p < 0.001$). While no mortality occurred in patients who were followed at home, mortality was observed in all hospitalized and followed up ($p = 0.002$). Admission in ICU and history of mechanical ventilation were not associated with mortality ($p = 0.08$ and 0.227, respectively), but the number of patients was very low for these parameters.

The Hosmer-Lemeshow test was applied for each final models resulted in $X^2=0.371$ $p = 0.831$ for mortality. These results revealed the built multiple binary logistic regression model's appropriateness in predicting the clinical outcomes in geriatric patients. Table 3 shows the univariate, adjusted, and multiple logistic regression analysis results identifying the risk factors of mortality. In univariate analysis, we found that people with intubation history increased the mortality risk 48.6 times (Odds Ratio: 48.60 95% CI 13.35-176.94, $p < 0.001$). History of intubation was not included in the multivariate analysis since it would suppress all other multivariate analysis parameters. Gender, polypharmacy, and the presence of COVID pneumonia parameters do not affect mortality in univariate analysis. We found that age was the only parameter affecting mortality in univariate analysis. When an adjusted model was established considering the effects of age and gender, that the variables of polypharmacy and the presence of COVID pneumonia do not affect mortality. In our study, the only factor that affects mortality was age. Patients aged 80 and over had a mortality rate of 6.82 times higher than patients aged 60-79 ($p < 0.001$). The same situation was similar in the multiple models.

Discussion

In the present study, the prevalence of polypharmacy in patients diagnosed with COVID-19 infection was 31.8%. Mortality occurred in 21.8% of the participants. There was no relationship between polypharmacy and mortality. The most important factor associated with mortality was older age.

Until now, quite a few studies have examined the relationship between polypharmacy and COVID-19. In one of them, De Smet et al [6]. reported a higher prevalence of polypharmacy than ours (64% vs. 31.8%), but the number of patients in this study was less than our study. Until now, there were very few publications on polypharmacy and COVID-19 related mortality. While no relationship was found between mortality and polypharmacy in one of these studies [6], another study found polypharmacy to increase the mortality risk [3]. Polypharmacy has been shown to increase mortality in older adults in many meta-analyses [11, 12]. However, surprisingly, this study did not show an association between polypharmacy and mortality (41.7% vs. 29.1%, $p=0.241$). Therefore, some things that affect outcomes in COVID-19 infection may be thought to be different from prognostic factors (age, sex, polypharmacy, and comorbidities) described in other cases.

Table 1. The characteristics of patients with COVID-19 (+) with or without mortality

Variables	Total n (%) n=110	Survivors n (%) n=86 (78.2)	Non- survivors n (%) n=24(21.8)	p
Age	70.50 (64.0-78.2)	69.00 (63.75-76.00)	79.50 (71.00-87.00)	<0.001
Age 60-79 80≥	87 (79.1) 23 (20.9)	75 (86.2) 11 (47.8)	12 (13.8) 12 (52.2)	<0.001
Gender Male Female	59 (53.6) 51 (46.4)	46 (78.0) 40 (78.4)	13 (22.0) 11 (21.6)	0.953
Comorbidity HT DM CAD COPD CKD Carcinoma	68 (61.8) 31 (28.2) 28 (25.5) 17 (15.5) 4 (3.6) 5 (4.5)	52 (60.50) 24 (27.90) 21 (24.40) 14 (16.30) 2 (2.30) 4 (4.7)	16 (66.70) 7 (29.20) 7 (29.20) 3 (12.50) 2 (8.30) 1 (4.2)	0.580 0.903 0.637 0.651 0.164
Number of comorbidity	2.0 (1.0-3.0)	2.0 (1.0-3.0)	2.0 (1.0-3.0)	0.572
Number of drugs	3.00 (1.00-5.20)	3.00 (1.00-5.00)	3.50 (2.00-6.00)	0.450
Polypharmacy	35 (31.80)	25 (29.10)	10 (41.70)	0.241
Presence of COVID pneumonia	82 (78.80)	67 (77.90)	15 (62.50)	0.126
Follow-up status Home Hospital	26 (23.60) 84 (76.40)	26 (30.20) 60 (69.80)	0 (0.0) 24 (100)	0.002
Admission on ICU	34 (30.90)	10 (11.60)	24 (100)	<0.001
Mechanical ventilation	5 (4.50)	5 (5.80)	18 (75.00)	<0.001

CAD Coronary Artery Disease, CKD Chronic Kidney Disease, COPD Chronic Obstructive Pulmonary Disease, COVID Coronavirus Disease, DM Diabetes Mellitus, HT Hypertension, ICU Intensive Care Unit.

Values are expressed as n (%) or median(1st-3rd quartiles). Adjusted p values are calculated using Benjamini-Hochberg procedure and significant adjusted p values are shown in bold

More research is needed to clarify the relationship between polypharmacy and COVID-19.

There were many studies in the literature that have examined various drug groups and the relationship of COVID-19. In some of these researches, the use of metformin [16, 17], DPP4-I [16], ACE-I [18-20], ARB [18-20], statins [20, 21] and chronic anticoagulants [22, 23] was protective against COVID-19-related mortality. However, results in other studies were in the opposite direction. Kocayigit and et al., found no association

between mortality and type of antihypertensive agents' use [24]. In the study of Cheng et al. [25], no effect of metformin use on mortality was found. In research investigating the relationship between many drug groups and mortality in Iran [26], only statin group drugs decreased mortality. In contrast, nonsteroidal anti-inflammatory drugs, ACE-I, and ARB use did not show any effect on death. In another study on diabetic COVID-19 patients [27], the use of antidiabetic agents (insulin, metformin, sulfonylurea, and DPP-4 inhibitors) did not have a protective effect on

Table 2. Comparison types of drugs between mortality

Variables	Survivors n (%) n=86 (78.2)	Non-survivors n (%) n=24 (21.8)	p
Any antihypertensive drugs			
ACE-I	20 (23.30)	4 (16.70)	0.586
ARB	24 (27.90)	7 (29.20)	0.903
Beta blocers	23 (26.70)	11 (45.80)	0.085
Calcium Channel Blocers	17 (65.40)	9 (37.50)	0.101
Diuretics	32 (37.20)	9 (37.50)	0.979
Alfa blocers	1 (4.20)	1 (1.20)	0.390
Any antiaggregant drugs			
ASA	9 (37.50)	23 (26.70)	0.305
Clopidogrel	6 (25.00)	11 (12.80)	0.143
Ticagrelor	0 (0.0)	2 (2.30)	0.451
Any anticoagulant drugs			
Warfarin	1 (4.20)	1 (1.20)	0.475
Rivaroxaban	0 (0.0)	2 (2.30)	
Immunosuppressant drugs	0 (0.0)	3 (3.50)	0.474
Inhaler drugs	3 (12.50)	14 (16.30)	0.464
Antidepressant drugs	0 (0.0)	7 (8.10)	0.169
Antilipidemic drugs	5 (20.80)	15 (17.40)	0.453
Any antidiabetic drug(AD)s			
Biguanides	2 (8.30)	19 (22.10)	0.129
DPP-IV inhibitors	7 (29.20)	23 (26.70)	0.814
Other oral ADs	2 (8.30)	4 (4.70)	0.390
Insulin	5 (20.80)	11 (12.80)	0.323
Proton pump inhibitors	5 (20.80)	9 (10.50)	0.178

Blockers, ASA Acetyl-Salicylic Acid, DPP Dipeptidyl Peptidase.

Values are expressed as n(%). Adjusted p values are calculated using Benjamini-Hochberg procedure and significant adjusted p values are shown in bold
ACE-I Angiotensin-Converting Enzyme Inhibitors, AD Antidiabetic Drug, ARB Angiotensin Receptor

Table 3. Univariate and multiple logistic regression analysis results in identifying the risk factors of mortality

	Crude Model		Adjusted Model		Multivariate Model	
	OR (95%CI)	p	OR (95%CI)	p	OR (95%CI)	p
Age, 60-79 80≥	6.82 (2.46-18.91) 1.00	<0.001 -	- -	- -	6.82 (2.46-18.91) 1.00	<0.001 -
Gender Male Female	0.97 (0.39-2.41) 1.00	0.953 -	- -	- -	- -	- -
Polypharmacy (>5 drugs)	1.74 (0.68-4.42)	0.244	1.78 (0.65-4.93)	0.264	-	-
Presence of COVID pneumonia	0.47 (0.18-1.25)	0.130	0.48 (0.16-1.37)	0.169	-	-

CI Confidence interval, COVID Coronavirus Disease, OR Odds ratio. Adjusted models are controlled for age and gender

mortality. The factors that were effective in drugs to prevent mortality in those researches improve the immune response, reduce the inflammatory response, block renin-angiotensin-aldosterone system, and prevent the formation of thrombosis [17, 19, 21, 22]. Our study examined the relationship between nine different drug groups (antihypertensive, antiaggregant, anticoagulant, immunosuppressant, inhaler, antidepressant, antilipidemic and antidiabetic drugs, and PPI) and mortality, and we found no relationship (Table 2). Randomized controlled studies are needed to understand precisely what the effects of drugs on COVID-19 related mortality.

When the patients with mortality in COVID-19 patients were examined in the literature, it was seen that 20–80% of them were over 60 years old [2, 4, 28, 29]. In some research in Turkey [3, 5], were like our research for over 60 years older patients (23.1% vs. 21.8%, 21.2% vs. 21.8%). When we divide it into groups by age, the mortality rates are similar to the literature and in Turkey [3, 30, 31]. In our research, the mortality rate between the ages of 60–79 was 13.8%, and over 80 years old, was 52.2%, respectively. We found that the mortality risk increased approximately seven times in individuals aged 80 and over. As in our research, many studies have reported that older age was a risk factor in COVID-19 related deaths [3, 6, 7, 15, 24, 28, 29]. Why is COVID-19 infection more mortal in older adults? Immunosenescence, or changes in the age-related immune system, primarily affects the adaptive immune system [32]. Accordingly, intracellular pathogens are more frequent and/or severe infections [33]. A decrease in T cell and B cell functions in relation to older age makes it challenging to limit viral replication [32]. Both older age and increasing type 2 cytokine production impairs cell-mediated immune responses to infectious challenge [32]. Also, susceptibility to thrombosis and thromboembolism increases with older age [32, 34–36]. Systemic inflammation is a condition that enhances procoagulant effects [34, 35]. Many studies published to date have found abnormalities in coagulation-related values in laboratory tests, and these abnormalities were associated with mortality in COVID-19 patients [2, 4, 37]. For these reasons, COVID-19 infection is more severe and mortal in older adults.

Study Limitations

There are some limitations to this study. The most important limitation was single-centered and of small sample size of the present study. Also, people with negative tests but radiologically with COVID-19 pneumonia were not included in this study. Therefore, the findings in this study, unfortunately, do not reflect all individuals with COVID-19 pneumonia. The government determines hospitalization and treatment algorithms for people diagnosed with COVID-19. So, there must be some selective bias. One of the limitations was that the presence of drug-drug interaction had not been studied. There was no information

about the laboratory parameters and treatment modalities of the participants. Therefore, the effects of the treatments received by individuals on mortality have not been studied. Further studies are still needed.

Conclusion

In summary, the prevalence of polypharmacy in individuals diagnosed with COVID-19 infection is like the literature. The most significant effect on mortality in people with COVID-19 infection is older age. Further studies with more participants are needed to clarify the relationship between COVID-19 infection and polypharmacy.

Ethics

Ethics Committee Approval: This study is approved by the Erciyes University Ethics Committee (date:10.06.2020, number:2020/285).

Informed Consent: Consent was obtained from the participants or their relatives.

Authorship Contributions

Concept: N.Ş.D. and S.A., Design: N.Ş.D. and S.A., Data Collection or Processing: N.Ş.D., S.A., T.S., and Z.T., Analysis or Interpretation: N.Ş.D., G.E.Z., and S.A Literature Search: N.Ş.D. and S.A, Writing: N.Ş.D. and S.A.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. <https://coronavirus.jhu.edu/map.html>.
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England)*. 2020; 395(10229): 1054–62.
3. Esme M, Koca M, Dikmeer A, Balci C, Ata N, Dogu BB, et al. Older Adults With Coronavirus Disease 2019; A Nationwide Study in Turkey. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2020.
4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet (London, England)*. 2020; 395(10223): 507–13.
5. Medetalibeyoğlu A, Senkal N, Kose M, Catma Y, Caparali EB, Erelel M, et al. Older adults hospitalized with Covid-19: Clinical characteristics and early outcomes from a single center in Istanbul, Turkey. 2020.
6. De Smet R, Mellaerts B, Vandewinckele H, Lybeert P, Frans E, Ombelet S, et al. Frailty and Mortality in Hospitalized Older Adults With COVID-19: Retrospective Observational Study. *Journal of the American Medical Directors Association*. 2020; 21(7): 928–32.e1.
7. Li T, Lu L, Zhang W, Tao Y, Wang L, Bao J, et al. Clinical characteristics of 312 hospitalized older patients with COVID-19 in Wuhan, China. *Archives of gerontology and geriatrics*. 2020; 91: 104185.

8. Ministry of Health - Republic of Turkey <https://covid19.saglik.gov.tr/>.
9. Franchi C, Tettamanti M, Pasina L, Djignefa CD, Fortino I, Bortolotti A, et al. Changes in drug prescribing to Italian community-dwelling elderly people: the EPIFARM-Elderly Project 2000-2010. *European journal of clinical pharmacology*. 2014; 70(4): 437-43.
10. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. *BMC geriatrics*. 2017; 17(1): 230.
11. Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. *Expert opinion on drug safety*. 2018; 17(12): 1185-96.
12. Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. *Journal of the American Academy of Nurse Practitioners*. 2005; 17(4): 123-32.
13. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. *Jama*. 2002; 287(3): 337-44.
14. Gutiérrez-Valencia M IM, Cesari M, Casas-Herrero Á, Inzitari M, Martínez-Velilla N. The relationship between frailty and polypharmacy in older people: A systematic review. *Br J Clin Pharmacol*. 2018; 84 (7): 1432-44.
15. Knopp P, Miles A. Presenting features of COVID-19 in older people: relationships with frailty, inflammation and mortality. 2020: 1-6.
16. Singh AK, Khunti K. Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A narrative review. *Diabetes research and clinical practice*. 2020; 165: 108266.
17. Luo P, Qiu L, Liu Y, Liu XL, Zheng JL, Xue HY, et al. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis. *The American journal of tropical medicine and hygiene*. 2020; 103(1): 69-72.
18. Rodilla E, Saura, A., Jiménez, I., Mendizábal, A., Pineda-Cantero, A., Lorenzo-Hernández, E., Fidalgo-Montero, M., López-Cuervo, J. F., Gil-Sánchez, R., Rabadán-Pejenaute, E., Abella-Vázquez, L., Giner-Galvañ, V., Solís-Marquín, M. N., Boixeda, R., Peña-Fernández, A., Carrasco-Sánchez, F. J., González-Moraleja, J., Torres-Peña, J. D., Guisado-Espartero, M. E., Escobar-Sevilla, J., ... Gómez-Huelgas, R. Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19. *Journal of clinical medicine*. 2020; 9(10): e 3136.
19. Chen R, Yang J, Gao X, Ding X, Yang Y, Shen Y, et al. Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension. 2020.
20. De Spiegeleer A, Bronselaer A, Teo JT, Byttebier G, De Tré G, Belmans L, et al. The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents. *Journal of the American Medical Directors Association*. 2020; 21(7): 909-14.e2.
21. Rodríguez-Nava G, Trelles-García DP, Yanez-Bello MA, Chung CW, Trelles-García VP, Friedman HJ. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. *Critical care (London, England)*. 2020; 24(1): 429.
22. Inama G, Dodi C, Provini M, Bossoni E, Inama L, Balzarini L, et al. Coronavirus disease 2019 infection in patients with recent cardiac surgery: does chronic anticoagulant therapy have a protective effect? *Journal of cardiovascular medicine (Hagerstown, Md)*. 2020; 21(10): 765-71.
23. Tremblay D, van Gerwen M, Alsen M, Thibaud S, Kessler A, Venugopal S, et al. Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study. *Blood*. 2020; 136(1): 144-7.
24. Kocayigit I KH, Yaylaci S, Can Y, Erdem AF, Karabay O. . Impact of antihypertensive agents on clinical course and in-hospital mortality: analysis of 169 hypertensive patients hospitalized for COVID-19. *Revista da Associacao Medica Brasileira*. 2020; 1992: 66. Suppl 2:71-6.
25. Cheng X, Liu YM, Li H, Zhang X, Lei F, Qin JJ, et al. Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. *Cell metabolism*. 2020; 32(4): 537-47.e3.
26. Alamdari NM, Afaghi S, Rahimi FS, Tarki FE, Tavana S, Zali A, et al. Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran. *The Tohoku journal of experimental medicine*. 2020; 252(1): 73-84.
27. Kim MK JJ, Kim SW, Moon JS, Cho NH, Han E, You JH, Lee JY, Hyun M, Park JS, Kwon YS, Choi YK, Kwon KT, Lee SY, Jeon EJ, Kim JW, Hong HL, Kwon HH, Jung CY, Lee YY, Ha E, Chung SM, Hur J, Ahn JH, Kim NY, Kim SW, Chang HH, Lee YH, Lee J, Park KG, Kim HA, Lee JH. The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea. *Diabetes & metabolism journal*. 2020; 44(4): 602-13.
28. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. *Respiratory research*. 2020; 21(1): 74.
29. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *The Journal of clinical investigation*. 2020; 130(5): 2620-9.
30. Ministry of Health - Republic of Turkey <https://saglik.gov.tr/>.
31. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? *Lancet (London, England)*. 2020; 395(10231): 1225-8.
32. Opal SM, Girard TD, Ely EW. The immunopathogenesis of sepsis in elderly patients. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2005; 41 Suppl 7: S504-12.
33. Grubeck-Loebenstien B, Wick G. The aging of the immune system. *Advances in immunology*. 2002; 80: 243-84.
34. Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. *Critical care (London, England)*. 2003; 7(1): 23-38.
35. Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. *The American journal of medicine*. 2003; 114(3): 180-7.
36. Yamamoto K, Takeshita K, Kojima T, Takamatsu J, Saito H. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. *Cardiovasc Res*. 2005; 66(2): 276-85.
37. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *The New England journal of medicine*. 2020; 382(18): 1708-20.